Merck & Co., Inc. (ETR:6MK)
Germany
· Delayed Price · Currency is EUR | Market Cap | 173.14B |
| Revenue (ttm) | 59.14B |
| Net Income (ttm) | 16.13B |
| Shares Out | n/a |
| EPS (ttm) | 6.36 |
| PE Ratio | 10.73 |
| Forward PE | 9.00 |
| Dividend | 2.91 (4.23%) |
| Ex-Dividend Date | Jun 16, 2025 |
| Volume | 1,651 |
| Average Volume | 3,208 |
| Open | 68.90 |
| Previous Close | 69.20 |
| Day's Range | 68.80 - 70.30 |
| 52-Week Range | 65.50 - 120.00 |
| Beta | 0.40 |
| RSI | 53.60 |
| Earnings Date | Jul 29, 2025 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janu... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial numbers in USD Financial StatementsNews
My Top 10 High-Yield Dividend Stocks For July 2025: One Yields 12%-Plus
I present my top 10 high-yield dividend stocks for July 2025, screened for strong yields, large market caps, and attractive valuations. The list includes Chevron, Pfizer, PepsiCo, Ares Capital, BB Seg...
Merck & Co.: A Pharma Titan At A Discount
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 9% (July 2025)
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filter...
Dr. Rasha Kelej Meets Mauritius President to Strengthen Partnership to Improve Access to Innovative and Equitable Healthcare and Empower Women in STEM
Senator, Dr. Rasha Kelej, CEO of Merck Foundation, the philanthropic arm of Merck KGaA Germany met HIS EXCELLENCY MR. DHARAMBEER GOKHOOL, The President of Republic of Mauritius, during a high-level me...
Summit said to be in talks with Astra to license potential rival for Merck’s Keytruda
Tech stocks soar: Semiconductors and software lead market gains
Sector Overview: Tech Takes the Lead The US stock market exhibited a remarkable tilt towards the technology sector today, with tech giants and semiconductors driving considerable gains. The sector at ...
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Merck's Hypertension Drug On FDA Fast Track For Label Expansion
The U.S. Food and Drug Administration (FDA) has accepted and granted priority review for Merck & Co. Inc.’s (NYSE: MRK) new supplemental Biologics License Application (sBLA) seeking approval to updat...
Merck granted FDA priority review for Winrevair label update
FDA Grants Priority Review for WINREVAIR (sotatercept-csrk) to Update Label Based on Results From ZENITH Trial
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a new supplementa...
FDA Grants Priority Review for WINREVAIR™ (sotatercept-csrk) to Update Label Based on Results From ZENITH Trial
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priori...
Top 15 High-Growth Dividend Stocks For July 2025
My Top 15 High-Growth Dividend Stocks outperformed SPY and VIG in June, gaining 6.15% versus SPY's 5.14% and VIG's 3.41%. The list's year-to-date return is 12.59%, beating SPY every month in 2025, tho...
Flow of funds moves into Dow and small cap stocks.
The market rotated out of the large-cap tech stocks today. Markets got a little spooked by better than expected JOLT job openings and the realization that July is probably not a month for a rate cut. ...
Top 10 High-Yield Dividend Stocks For July 2025
My July 2025 watchlist focuses on high-yield, attractively valued stocks, aiming for a 12% long-term CAGR and outperforming benchmarks. Since its inception, my watchlist has a CAGR of 15.11%, performi...
Dividend Yield Theory Says Merck Is A Buy
Merck Foundation Chairman, CEO, and 14 First Ladies Inaugurate the 7th Edition of Merck Foundation First Ladies Initiative - MFFLI Summit in Dubai
DUBAI, United Arab Emirates--(BUSINESS WIRE)-- #CEO--Merck Foundation conducted the 7th Edition of Merck Foundation First Ladies Initiative - MFFLI Summit 2025 in Dubai, United Arab Emirates.
Merck to Hold Second-Quarter 2025 Sales and Earnings Conference Call July 29
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its second-quarter 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET ...
Merck to Hold Second-Quarter 2025 Sales and Earnings Conference Call July 29
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold Second-Quarter 2025 Sales and Earnings Conference Call July 29.
Peering Into Merck & Co's Recent Short Interest
Merck & Co's (NYSE: MRK) short percent of float has risen 3.92% since its last report. The company recently reported that it has 35.80 million shares sold short , which is 1.59% of all regular shares...
Merck: Don't Let Today's Bargain Opportunity Pass You By
Merck remains a top Big Pharma brand with strong management, expected sales growth, and high profit margins, helped by the revolutionary Keytruda invention.
Merck: Cheap Stock, But Still Relying Heavily On Keytruda (Rating Upgrade)
Merck & Co., Inc.'s heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other products. Valuation has become attractive after a significant s...
40% Upside For Merck Stock?
Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically positioning itself for further growth by diversifying and expanding its pipelin...
US stocks threatens to close at record levels but closes just off record levels
The broader stock indices threatened to close at record levels with the S&P index getting within one point of a record high level. The comes in at 6147.43. The high price today reached 6146.52. The NA...
Merck's RSV shot for infants gets key approval despite RFK Jr.'s panel shakeup
Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., who has previously made statements skeptical of vaccines, is now recommending the respiratory syncytial virus (RSV) vaccine for infants...
Elanco Animal Health Gets Its Bite Back, Pipeline Efforts Earn Praise
After years of struggling with market share losses and uneven execution, Elanco Animal Health Incorporated (NYSE: ELAN) appears to be turning a corner . What Happened : Investor meetings hosted by Wi...